Definitive Healthcare Corp. Stock

Equities

DH

US24477E1038

Software

Market Closed - Nasdaq 04:00:00 2024-05-20 pm EDT 5-day change 1st Jan Change
5.67 USD +3.09% Intraday chart for Definitive Healthcare Corp. +4.42% -42.96%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 258M Sales 2025 * 273M Capitalization 649M
Net income 2024 * -33M Net income 2025 * -20M EV / Sales 2024 * 2.28 x
Net cash position 2024 * 60.93M Net cash position 2025 * 108M EV / Sales 2025 * 1.98 x
P/E ratio 2024 *
-19.8 x
P/E ratio 2025 *
-21.7 x
Employees 950
Yield 2024 *
-
Yield 2025 *
-
Free-Float 32.37%
More Fundamentals * Assessed data
Dynamic Chart
Barclays Adjusts Price Target on Definitive Healthcare to $7 From $11, Maintains Equal-Weight Rating MT
Deutsche Bank Adjusts Definitive Healthcare Price Target to $7 From $10, Maintains Hold Rating MT
Stifel Adjusts Price Target on Definitive Healthcare to $9.50 From $11, Maintains Buy Rating MT
Morgan Stanley Downgrades Definitive Healthcare to Equalweight From Overweight, Cuts Price Target to $9 From $11.50 MT
Transcript : Definitive Healthcare Corp., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (DH) DEFINITIVE HEALTHCARE Reports Q1 Revenue $63.5M, vs. Street Est of $64M MT
Earnings Flash (DH) DEFINITIVE HEALTHCARE Posts Q1 EPS $0.08, vs. Street Est of $0.08 MT
Definitive Healthcare Corp. (NasdaqGS:DH) announces an Equity Buyback for $20 million worth of its shares. CI
Definitive Healthcare Corp. Provides Earnings Guidance for the Second Quarter and Full Year 2024 CI
Definitive Healthcare Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Definitive Healthcare Corp. authorizes a Buyback Plan. CI
Definitive Healthcare Introduces Carevoyance Sales Enablement Solution for Medtech Industry CI
Definitive Healthcare Collaborating With VML Health on Key Opinion Leader Management Tool for Clients MT
Definitive Healthcare and VML Health Announce Partnership to Transform Key Opinion Leader Management CI
Deutsche Bank Adjusts Definitive Healthcare Price Target to $10 From $9, Maintains Hold Rating MT
More news
1 week+3.38%
Current month-20.75%
1 month-22.10%
3 months-44.94%
6 months-32.43%
Current year-44.67%
More quotes
1 week
5.35
Extreme 5.35
5.70
1 month
4.38
Extreme 4.38
7.57
Current year
4.38
Extreme 4.38
10.62
1 year
4.38
Extreme 4.38
12.46
3 years
4.38
Extreme 4.38
50.30
5 years
4.38
Extreme 4.38
50.30
10 years
4.38
Extreme 4.38
50.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 11-01-31
President 46 22-11-02
Director of Finance/CFO 54 21-02-28
Members of the board TitleAgeSince
Director/Board Member 56 21-09-30
Director/Board Member 47 19-06-30
Director/Board Member 46 15-01-31
More insiders
Date Price Change Volume
24-05-20 5.67 +3.09% 906 572
24-05-17 5.5 0.00% 690,582
24-05-16 5.5 -1.26% 680,871
24-05-15 5.57 +2.20% 2,015,514
24-05-14 5.45 +0.37% 937,465

Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT

More quotes
Definitive Healthcare Corp. is engaged in transforming data, analytics, and expertise into healthcare commercial intelligence. The Company’s solutions are designed to provide information on healthcare providers and their activities to help its customers optimize everything from product development to go-to-market planning and sales and marketing execution. Its software-as-a-service (SaaS) platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers and improving win rates with detailed contextual information. It transforms data into intelligence through artificial intelligence (AI) and machine learning (ML) algorithms that ingest, cleanse, link, and analyze the data to create new intelligence and analytics. All of its business is conducted through AIDH TopCo, LLC (Definitive OpCo).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
5.5 USD
Average target price
8.45 USD
Spread / Average Target
+53.64%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW